|
1
|
Zhu AX: Molecularly targeted therapy for
advanced hepatocellular carcinoma in: 2012 Current status and
future perspectives. Semin Oncol. 39:493–502. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Psyrri A, Arkadopoulos N, Vassilakopoulou
M, Smyrniotis V and Dimitriadis G: Pathways and targets in
hepatocellular carcinoma. Expert Rev Anticancer Ther. 12:1347–1357.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dimitrova V and Arcaro A: Targeting the
PI3K/AKT/mTOR signaling pathway in medulloblastoma. Curr Mol Med.
15:82–93. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ohta K, Hoshino H, Wang J, Ono S, Iida Y,
Hata K, Huang SK, Colquhoun S and Hoon DS: MicroRNA-93 activates
c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by
directly inhibiting PTEN and CDKN1A. Oncotarget. 6:3211–3224. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang Y, Hu C, Cheng J, Chen B, Ke Q, Lv Z,
Wu J and Zhou Y: MicroRNA-145 suppresses hepatocellular carcinoma
by targeting IRS1 and its downstream Akt signaling. Biochem Biophys
Res Commun. 446:1255–1260. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang HY, Yang SL, Liang HF and Li CH: HBx
protein promotes oval cell proliferation by up-regulation of cyclin
D1 via activation of the MEK/ERK and PI3K/Akt pathways. Int J Mol
Sci. 15:3507–3518. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Carnero A and Paramio JM: The
PTEN/PI3K/AKT pathway in vivo, cancer mouse models. Front Oncol.
4:2522014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Eng C: PTEN: One gene, many syndromes. Hum
Mutat. 22:183–198. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hers I, Vincent EE and Tavaré JM: Akt
signalling in health and disease. Cell Signal. 23:1515–1527. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Donald S, Hill K, Lecureuil C, Barnouin R,
Krugmann S, Coadwell John W, Andrews SR, Walker SA, Hawkins PT,
Stephens LR and Welch HC: P-Rex2, a new guanine-nucleotide exchange
factor for Rac. FEBS Lett. 572:172–176. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Donald S, Humby T, Fyfe I, Segonds-Pichon
A, Walker SA, Andrews SR, Coadwell WJ, Emson P, Wilkinson LS and
Welch HC: P-Rex2 regulates Purkinje cell dendrite morphology and
motor coordination. Proc Natl Acad Sci USA. 105:4483–4488. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fine B, Hodakoski C, Koujak S, Su T, Saal
LH, Maurer M, Hopkins B, Keniry M, Sulis ML, Mense S, et al:
Activation of the PI3K pathway in cancer through inhibition of PTEN
by exchange factor P-REX2a. Science. 325:1261–1265. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Guo B, Liu L, Yao J, Ma R, Chang D, Li Z,
Song T and Huang C: miR-338-3p suppresses gastric cancer
progression through a PTEN-AKT axis by targeting P-REX2a. Mol
Cancer Res. 12:313–321. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen X, Pan M, Han L, Lu H, Hao X and Dong
Q: miR-338-3p suppresses neuroblastoma proliferation, invasion and
migration through targeting PREX2a. FEBS Lett. 587:3729–3737. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Berger MF, Hodis E, Heffernan TP, Deribe
YL, Lawrence MS, Protopopov A, Ivanova E, Watson IR, Nickerson E,
Ghosh P, et al: Melanoma genome sequencing reveals frequent PREX2
mutations. Nature. 485:502–506. 2012.PubMed/NCBI
|
|
16
|
Lan X, Xiao F, Ding Q, Liu J, Liu J, Li J,
Zhang J and Tian DA: The effect of CXCL9 on the invasion ability of
hepatocellular carcinoma through up-regulation of PREX2. J Mol
Histol. 45:689–696. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hung CH, Chiu YC, Chen CH and Hu TH:
MicroRNAs in hepatocellular carcinoma: Carcinogenesis, progression,
and therapeutic target. Biomed Res Int. 2014:4864072014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hodakoski C, Hopkins BD, Barrows D, Mense
SM, Keniry M, Anderson KE, Kern PA, Hawkins PT, Stephens LR and
Parsons R: Regulation of PTEN inhibition by the pleckstrin homology
domain of P-REX2 during insulin signaling and glucose homeostasis.
Proc Natl Acad Sci USA. 111:155–160. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Salmena L, Carracedo A and Pandolfi PP:
Tenets of PTEN tumor suppression. Cell. 133:403–414. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Trotman LC, Niki M, Dotan ZA, Koutcher JA,
Di Cristofano A, Xiao A, Khoo AS, Roy-Burman P, Greenberg NM, Van
Dyke T, et al: Pten dose dictates cancer progression in the
prostate. PLoS Biol. 1:E592003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Oishi N, Yamashita T and Kaneko S:
Molecular biology of liver cancer stem cells. Liver Cancer.
3:71–84. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pandiella A and Montero JC: Molecular
pathways: P-Rex in cancer. Clin Cancer Res. 19:4564–4569. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Leslie NR: P-REX2a driving tumorigenesis
by PTEN inhibition. Sci Signal. 2:pe682009. View Article : Google Scholar : PubMed/NCBI
|
